Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CD74 | P04233 | 2/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783485 | 0.86 | CYP11B2 (0.43) | CYP2A6PDE10ASMN1; SMN2CYP11B2CYP11B1 | |
| SCHEMBL782302 | 0.73 | CYP11B2 (0.40) | CYP2A6PDE10AALDH1A1SMN1; SMN2CYP11B2 | |
| SCHEMBL783473 | 0.67 | CYP11B2 (0.54) | CYP11B2CYP11B1KMT2A | |
| SCHEMBL782295 | 0.67 | CYP11B2 (0.43) | SMN1; SMN2CYP11B2KMT2A | |
| SCHEMBL783487 | 0.66 | KCNJ1 (0.51) | PDE10ACYP11B2CYP11B1TNIK | |
| SCHEMBL16014515 | 0.65 | CYP11B1 (0.65) | CYP11B2CYP11B1 | |
| SCHEMBL805384 | 0.64 | MEN1 (0.43) | ALDH1A1SMN1; SMN2CYP11B2KMT2A | |
| SCHEMBL14987939 | 0.64 | PDE10A (0.45) | PDE10A | |
| SCHEMBL13961602 | 0.63 | CD74 (0.64) | CD74MIFKMT2A | |
| SCHEMBL30665855 | 0.61 | KMO (0.45) | PDE10AALDH1A1SMN1; SMN2CD74MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | CYP2A6 67/4885PDE10A 298/4885ALDH1A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.